AUSTIN, Texas – Feb. 12, 2025 – Global law firm Greenberg Traurig, LLP grew its Life Sciences & Medical Technology Practice with the addition of Shareholder Can Cui in its Austin office. Cui joins the firm from Goodwin, where he served as co-leader of the firm’s Life Sciences practice in Asia.
“Recruiting and retaining top talent like Can is a key component of our firm's growth strategy, focusing on key practice areas and markets that matter most to clients. With 15 international and 34 domestic offices, Greenberg Traurig enables clients to access our full service-full life cycle expertise in a global life sciences industry,” said Richard A. Rosenbaum, Greenberg Traurig Executive Chairman.
“We are certain that Can's expertise and well-regarded reputation will enhance our already robust global team. Texas remains one of the fastest-growing markets, and we are thrilled to welcome a leader in Life Sciences and Medical Technology to the region,” said Shari L. Heyen and Demetrius G. McDaniel, co-regional shareholders of the firm’s Texas offices.
Cui has a global reputation representing clients on technology transactions and investments in the life sciences industry, with an emphasis on cross-border deals involving Asia, particularly China. His work encompasses technology licensing and acquisition, collaboration and strategic partnerships, joint ventures, and various forms of investment.
Cui represents both licensors and licensees in U.S.-Asia life sciences licensing deals. In private equity and venture capital sector, he frequently handles IP due diligence and negotiates investment documents for investors, established companies, and startups. He also advises on IP issues in mergers and acquisitions.
“Can joins us with an unparalleled scientific background and an impressive reputation in the legal community, ” said Scott J. Bornstein, senior vice president of the firm, co-managing shareholder of the New York office, and co-chair of the Global Intellectual Property & Technology and Global Patent Litigation Groups. “He will further strengthen Greenberg Traurig’s global Life Sciences & Medical Technology Practice, help to connect our clients, and fit their needs in Texas and beyond.”
“Greenberg Traurig's global platform perfectly complements my practice and provides an opportunity for growth. The firm offers a unique international perspective as well as local expertise in key markets of the Life Sciences and Medical Technology industries,” Cui said. “I look forward to working in Austin, a city that is quickly becoming a next-generation biotech hub, and contributing not only to the firm’s Texas offices, but also to its global Life Sciences and Medical Technology Practice, particularly serving clients doing transactions throughout the United States and Asia. Being part of the Greenberg Traurig team offers an incredible chance to be at the forefront of industry innovation, while providing exceptional services to clients world-wide.”
Before becoming a licensed attorney, Cui honed his expertise as a U.S. patent agent. He received his J.D. from New York University School of Law and holds a Ph.D. in Biological Chemistry & Molecular Pharmacology from Harvard University, and a B.Sc. in Biotechnology from Peking University. As a graduate student at Harvard, Cui initiated and led a major long-term collaboration among Harvard Medical School, the University of California, San Diego, and the Chinese Academy of Sciences. His groundbreaking work in identifying a viral microRNA was highlighted in the Journal of Virology's “Spotlight” section for its significant contribution to the field.
Admitted in Texas, California, and New York, Cui will work closely with team members throughout the firm’s 49 offices. He joins the firm alongside recently added Life Sciences & Medical Technology Shareholders Christopher C. Bolten and Robert D. Ward, and Of Counsel Albert K. Heng, who joined in California.
In addition to Cui, the firm’s three offices in Texas have recently added strategically chosen attorneys in core areas, including Shareholders Jera L. Bradshaw in Banking & Financial Services, Gemma Descoteaux in Corporate, Rob LeBlanc in Intellectual Property & Technology, Kurt Lyn in Corporate, Ashley N. Moore in Intellectual Property & Technology, and Drew Slone in Public Finance & Infrastructure. Additional growth is expected shortly across the state.
About Greenberg Traurig’s Life Sciences & Medical Technology Group: Greenberg Traurig’s nationally ranked Life Sciences & Medical Technology Group advises clients ranging from start-ups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through development, commercialization and product marketing.
About Greenberg Traurig: Greenberg Traurig, LLP has more than 2750 attorneys in 49 locations in the United States, Europe and the Middle East, Latin America, and Asia. The firm is a 2024 BTI “Leading Edge Law Firm” for delivering on client expectations for the future and is consistently among the top firms on the Am Law Global 100 and NLJ 500. Greenberg Traurig is Mansfield Rule Certified Plus by The Diversity Lab. The firm is recognized for powering its U.S. offices with 100% renewable energy as certified by the Center for Resource Solutions Green-e® Energy program and is a member of the U.S. EPA’s Green Power Partnership Program. The firm is known for its philanthropic giving, innovation, diversity, and pro bono. Web: www.gtlaw.com.